Cargando…
Regulatory and policy tools to address unproven stem cell interventions in Canada: the need for action
BACKGROUND: The marketing of unproven direct-to-consumer stem cell interventions is becoming widespread in Canada. There is little evidence supporting their use and they have been associated with a range of harms. Canada has been slower to act against clinics offering these interventions than other...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6683337/ https://www.ncbi.nlm.nih.gov/pubmed/31383026 http://dx.doi.org/10.1186/s12910-019-0388-4 |
_version_ | 1783442069557084160 |
---|---|
author | Caulfield, Timothy Murdoch, Blake |
author_facet | Caulfield, Timothy Murdoch, Blake |
author_sort | Caulfield, Timothy |
collection | PubMed |
description | BACKGROUND: The marketing of unproven direct-to-consumer stem cell interventions is becoming widespread in Canada. There is little evidence supporting their use and they have been associated with a range of harms. Canada has been slower to act against clinics offering these interventions than other jurisdictions, including the United States. Here, we outline the regulatory and policy tools available in Canada to address this growing problem. MAIN BODY: Health Canada’s regulations governing cell therapies are complex, but recent statements make it clear that Health Canada believes it has jurisdiction over many of the currently marketed stem cell interventions. Still, further regulatory clarity is needed from Health Canada, as are increased directed enforcement efforts on interventions that fall within their scope. The Competition Bureau, via the Competition Act, prohibits advertisers from making materially false or misleading promotional representations. The Competition Bureau could collaborate with the scientific community to analyze the claims of existing clinics in Canada, and impose sanctions upon those who breach the established standard. Professional regulators, including provincial colleges of physicians and surgeons, have considerable power over what products and services their members can offer. Every college of physicians in Canada requires, via policy and codes of ethics, that doctors maintain evidence-based practices. This requirement is incompatible with offering many unproven stem cell interventions. Litigation may be another tool, including the use of fraud, misrepresentation and/or negligence claims for failing to meet the required standard of care. Finally, political pressure on federal and provincial lawmakers could encourage changes to marketing, cell therapy and professional regulations that would allow a more comprehensive response. CONCLUSIONS: In sum, there are many existing tools that can be used to protect the public from unproven stem cell interventions. Increased bureaucratic will and grassroots efforts are needed in order to effect a positive policy response. |
format | Online Article Text |
id | pubmed-6683337 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-66833372019-08-09 Regulatory and policy tools to address unproven stem cell interventions in Canada: the need for action Caulfield, Timothy Murdoch, Blake BMC Med Ethics Debate BACKGROUND: The marketing of unproven direct-to-consumer stem cell interventions is becoming widespread in Canada. There is little evidence supporting their use and they have been associated with a range of harms. Canada has been slower to act against clinics offering these interventions than other jurisdictions, including the United States. Here, we outline the regulatory and policy tools available in Canada to address this growing problem. MAIN BODY: Health Canada’s regulations governing cell therapies are complex, but recent statements make it clear that Health Canada believes it has jurisdiction over many of the currently marketed stem cell interventions. Still, further regulatory clarity is needed from Health Canada, as are increased directed enforcement efforts on interventions that fall within their scope. The Competition Bureau, via the Competition Act, prohibits advertisers from making materially false or misleading promotional representations. The Competition Bureau could collaborate with the scientific community to analyze the claims of existing clinics in Canada, and impose sanctions upon those who breach the established standard. Professional regulators, including provincial colleges of physicians and surgeons, have considerable power over what products and services their members can offer. Every college of physicians in Canada requires, via policy and codes of ethics, that doctors maintain evidence-based practices. This requirement is incompatible with offering many unproven stem cell interventions. Litigation may be another tool, including the use of fraud, misrepresentation and/or negligence claims for failing to meet the required standard of care. Finally, political pressure on federal and provincial lawmakers could encourage changes to marketing, cell therapy and professional regulations that would allow a more comprehensive response. CONCLUSIONS: In sum, there are many existing tools that can be used to protect the public from unproven stem cell interventions. Increased bureaucratic will and grassroots efforts are needed in order to effect a positive policy response. BioMed Central 2019-08-06 /pmc/articles/PMC6683337/ /pubmed/31383026 http://dx.doi.org/10.1186/s12910-019-0388-4 Text en © The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Debate Caulfield, Timothy Murdoch, Blake Regulatory and policy tools to address unproven stem cell interventions in Canada: the need for action |
title | Regulatory and policy tools to address unproven stem cell interventions in Canada: the need for action |
title_full | Regulatory and policy tools to address unproven stem cell interventions in Canada: the need for action |
title_fullStr | Regulatory and policy tools to address unproven stem cell interventions in Canada: the need for action |
title_full_unstemmed | Regulatory and policy tools to address unproven stem cell interventions in Canada: the need for action |
title_short | Regulatory and policy tools to address unproven stem cell interventions in Canada: the need for action |
title_sort | regulatory and policy tools to address unproven stem cell interventions in canada: the need for action |
topic | Debate |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6683337/ https://www.ncbi.nlm.nih.gov/pubmed/31383026 http://dx.doi.org/10.1186/s12910-019-0388-4 |
work_keys_str_mv | AT caulfieldtimothy regulatoryandpolicytoolstoaddressunprovenstemcellinterventionsincanadatheneedforaction AT murdochblake regulatoryandpolicytoolstoaddressunprovenstemcellinterventionsincanadatheneedforaction |